关爱生命与健康 为人类健康做出贡献
在2026年神经肿瘤学会(Society for Neuro-Oncology,SNO)年会上,公司自主研发的JRF101(脂质体注射制剂)用于治疗复发性胶质母细胞瘤(Recurrent Glioblastoma,GBM)的最新临床研究进展正式亮相。
Jinrui recently attended the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, where members of the company s team met with biotechnology and pharmaceutical industry representatives from North America, Europe, and Asia